---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-23-000048"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2023-08-11T23:59:59+00:00"
generated_at: "2026-06-11T14:32:01.324919+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Elicio posts Q2 net loss $7.6M, cash $21.7M; reports interim AMPLIFY-201 data

## Summary
- Net loss $7.6M ($2.61/share) vs $7.3M; cash $21.7M at June 30 vs $6.2M at Dec 31, 2022.
- R&D expense $4.9M, G&A $2.8M (up vs $1.2M) due to reverse merger and public company costs.
- AMPLIFY-201 interim data: ELI-002 induced mKRAS T-cell response (56-fold avg); tumor biomarker reduced in 77% of patients.
- AMPLIFY-7P Phase 1A enrollment initiated for ELI-002 7P; Phase 1B RP2D initiation expected Q3 2023.
- Completed reverse merger in Q2 2023; common stock now trading on Nasdaq.

## SEC filing metadata
- accession: 0001601485-23-000048
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2023-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148523000048/0001601485-23-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148523000048/angn-20230811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-23-000048
- JSON: https://secwatch.observer/filing/0001601485-23-000048.json
- Plain text: https://secwatch.observer/filing/0001601485-23-000048.txt

## Key facts
- Earnings Releases
  Elicio Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss for the second quarter of 2023 was $7.6 million, EPS Net loss per share for the second quarter of 2023 was $2.61.
  - Period: the second quarter ended June 30, 2023
  - Net income: Net loss for the second quarter of 2023 was $7.6 million
  - EPS: Net loss per share for the second quarter of 2023 was $2.61
  - Result: reported results
  source text: Elicio Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601485/000160148523000048/0001601485-23-000048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.